Mark D. Seltzer

In the news

• Law360

  J&J hip implant FCA case tossed over secret info use

  This article covers a significant litigation win, in which a federal judge dismissed a nearly decade-long False Claims Act lawsuit against Johnson & Johnson entities over allegedly defective hip replacement devices, noting that two whistleblower physicians used confidential information in their complaint. The article mentions Boston partners Mark Seltzer and Hannah Bornstein and associate Colin Missett, and Washington, DC partner Adam Tarosky—all of the Government Investigations & White-Collar Defense group—for representing J&J and its related entities.
  Dec 8, 2021
• Law360

  Doctors say no secret info used in FCA suit against J&J

  This article mentions Boston Government Investigations and White-Collar Defense partners Hannah Bornstein and Mark Seltzer for their representation of the defendants in a False Claims Act suit centering on faulty hip replacement devices. The defendants have argued the suit should be dismissed on the grounds that confidential information was used in the complaint.
  March 6, 2020
• Reuters Legal

  GSK wins access to records on researcher’s link to Zofran plaintiffs’ lawyers

  This story mentions Boston Government Investigations and White Collar Defense partner Mark Seltzer for his representation of GlaxoSmithKline in an ongoing matter regarding the drugmaker’s antinausea medication, Zofran.
  July 25, 2019
• Law360

  GSK gets 2nd chance to argue preemption in Zofran MDL

  The following articles mention Boston Government Investigations and White Collar Defense partners Mark Seltzer and Brian French for their representation of GlaxoSmithKline in an ongoing matter related to the pharmaceutical company’s anti-nausea drug Zofran. One of the issues is whether federal law pre-empts state law in the case.
  July 10, 2019
• Reuters Legal

  Judge to seek FDA’s views on Zofran birth defect cases against GSK

  The following articles mention Boston Government Investigations and White Collar Defense partners Mark Seltzer and Brian French for their representation of GlaxoSmithKline in an ongoing matter related to the pharmaceutical company’s anti-nausea drug Zofran. One of the issues is whether federal law pre-empts state law in the case.
  July 10, 2019
• Reuters Legal

  GSK renews Zofran birth defect dismissal bid after Supreme Court ruling

  This article mentions Boston Government Investigations and White Collar Defense partner Mark Seltzer for his representation of GlaxoSmithKline in an ongoing matter related to its anti-nausea medication Zofran.
  June 4, 2019
• Reuters Legal

  GSK fights to subpoena publisher of Zofran study by plaintiffs' consultant

  Boston Government Investigations & White Collar Defense partner Mark Seltzer is mentioned in this story for his representation of pharmaceutical company GlaxoSmithKline in an ongoing matter related to the company’s anti-nausea drug Zofran.
  April 3, 2019
• Reuters

  GSK accuses Zofran plaintiffs' law firms of funding academic study

  Boston Government Investigations and White Collar Defense partner Mark Seltzer is mentioned in this article for representing GlaxoSmithKline in an ongoing dispute related to the company’s anti-nausea drug Zofran.
  March 5, 2019
• Law360

  FDA never saw birth-defect tests on GSK drug, families say

  Boston Government Investigations & White Collar Defense partners Mark Seltzer and Brian French are mentioned in this article for their ongoing representation of GlaxoSmithKline in a suit regarding their drug Zofran.
  Sep 13, 2018
• Law360

  GSK Zofran users bicker over scope of patient discovery

  Boston government investigations and white collar defense partners Mark Seltzer and Brian French are mentioned in this story for their representation of pharmaceutical company GlaxoSmithKline in a lawsuit brought by users of its anti-nausea medication Zofran.
  April 25, 2018
• Law360

  J&J won't get high court look at FCA 'particularity' rule

  In the following coverage, Boston government investigations and white-collar defense partners Mark Seltzer and Hannah Bornstein are mentioned for their ongoing representation of Johnson & Johnson and its subsidiary DePuy Orthopaedics Inc. in a False Claims Act case. The Supreme Court recently declined to review the First Circuit’s ruling in the case.
  April 16, 2018
• Reuters Legal

  U.S. Supreme Court declines to review whistleblower case against J&J's DePuy

  In the following coverage, Boston government investigations and white-collar defense partners Mark Seltzer and Hannah Bornstein are mentioned for their ongoing representation of Johnson & Johnson and its subsidiary DePuy Orthopaedics Inc. in a False Claims Act case. The Supreme Court recently declined to review the First Circuit’s ruling in the case.
  April 16, 2018
• Law360

  J&J unit wants whistleblower docs in hip implant FCA suit

  Boston government investigations and white-collar defense partners Mark Seltzer and Hannah Bornstein are mentioned in this article for representing Johnson & Johnson Services Inc. and its subsidiary DePuy Orthopaedics in a suit alleging violations of the False Claims Act.
  April 12, 2018
• Law360

  Judge keeps fraud claims against GSK alive in Zofran MDL

  Boston government investigations and white collar defense partner Mark Seltzer and commercial litigation associate Josh Barlow are mentioned in this article about their client, GlaxoSmithKline PLC, in a case regarding labeling related to the use of the anti-nausea drug Zofran during pregnancy.
  April 24, 2017
• Law360

  GSK says no basis for fraud claims in Zofran MDL

  Boston government investigations and white collar defense partner Mark Seltzer and commercial litigation associate Josh Barlow are noted as representing GlaxoSmithKline (GSK) in this article about recent developments in a multidistrict litigation (MDL) about GSK’s anti-nausea drug Zofran.
  Jan 27, 2017
• Law360

  J&J asks 1st Circ. to halt hip implant FCA suit

  Boston government investigations and white collar defense partners Mark Seltzer and Danielle Pelot and associate Hannah Bornstein are listed as counsel representing Johnson & Johnson and its subsidiary DePuy in a First Circuit case. This article notes their argument to uphold the dismissal of a False Claims Act lawsuit.
  Dec 6, 2016
• Law360

  Judge will hear GSK's arguments to dismiss Zofran MDL

  This story covers a recent decision by a Boston federal judge to hear GlaxoSmithKline’s (GSK) arguments to discuss some cases and claims from its multidistrict litigation focused on the anti-nausea medication Zofran.  Boston Government Investigations & White Collar Defense partner Mark Seltzer and Commercial Litigation associate Josh Barlow are noted as representing GSK.
  Nov 11, 2016